$40.96
0.190.47%
Últ. Act.: Oct 28, 4:35 AM
Supernus Pharmaceuticals (SUPN) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Supernus Pharmaceuticals (SUPN) publicó su última previsión de agosto 3, 2026 para fiscal year 2026. La compañía estimó ingresos en un rango de $860M - $890M para el período.
En comparación con la previsión anterior, Supernus Pharmaceuticals elevado redujo su previsión de ingresos desde un rango anterior de $840M - $870M.
Supernus Pharmaceuticals ha emitido 16 actualizaciones de orientación entre el noviembre 8, 2022 y el agosto 3, 2026. During this period, the company raised its outlook 6 times and lowered it 2 times, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.42 | $0.25 | $0.22 | $0.62 |
| Actual | $0.53 | $-0.04 | $-0.07 | $-0.80 |
| Surprise | +26.2% | -116.0% | -131.8% | -229.0% |
| Revenue | ||||
| Estimate | $205.5M | $192.0M | $195.8M | $181.0M |
| Actual | $219.1M | $207.7M | $211.6M | $192.1M |
| Surprise | +6.59% | +8.17% | +8.07% | +6.16% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E |
|---|---|---|---|
| Earnings Per Share (Non-GAAP) | |||
| Consensus | $0.46 | $0.93 | $0.39 |
| Revenue | |||
| Consensus | $218.8M | $231.2M | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 3, 2026 | $0.53 | $0.42 | 26.2 % |
| Q1 | May 5, 2026 | $-0.04 | $0.25 | -116.0 % |
| Q4 | Feb 24, 2026 | $-0.07 | $0.22 | -131.8 % |
| Q3 | Nov 4, 2025 | $-0.80 | $0.62 | -229.0 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 3, 2026 | $219.06M | $205.51M | 6.59 % |
| Q1 | May 5, 2026 | $207.71M | $192.02M | 8.17 % |
| Q4 | Feb 24, 2026 | $211.57M | $195.77M | 8.07 % |
| Q3 | Nov 4, 2025 | $192.10M | $180.96M | 6.16 % |